🚨 Exciting News! 🚨 We’re thrilled to announce our collaboration with Menarini Stemline to enhance the early identification of Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)—a rare but aggressive blood cancer. We are proud to enhance our AI to support healthcare providers in recognizing potential signs of BPDCN earlier, leading to improved patient outcomes.
This content is intended for U.S. audiences only. Menarini Group announced a collaboration with VisualDx to aid in identifying people who may have blastic plasmacytoid dendritic cell neoplasm (BPDCN). Read today’s press release here: https://bit.ly/4hoHFHF